CT-707 is a mutant-selective inhibitor of ALK/focal adhesion kinase (FAK) and IGFR1 and it is designed to be a targeted therapeutic agent for NSCLC patients harboring ALK active and crizotinib-resistant mutations (13,14). The gene discussed is ALK; the disease is non-small cell lung carcinoma.